Company profile
Weatherden | Better drugs, faster
Weatherden is a pioneering drug development route-to-market design, strategy and execution consulting group, optimising clinical, regulatory, and commercial pathways from discovery to exit and accelerating the translation of novel science into life-changing medicines for patients.
Updated 07 Jul 2026 09:49
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
PSC07 | Transaction MzQ0NDI5MzYzM2FkaXF6a2N4
Published 20 Nov 2024 02:53
PSC04 | Transaction MzQ0NDI5MzMxMGFkaXF6a2N4
Published 20 Nov 2024 02:51
TM01 | Transaction MzQ0NDI4MTc0NGFkaXF6a2N4
Published 20 Nov 2024 01:09
AP01 | Transaction MzQ0NDI4MTY0NWFkaXF6a2N4
Published 20 Nov 2024 01:08
CS01 | Transaction MzQzODcxMTM3NGFkaXF6a2N4
Published 08 Oct 2024 09:49
Company registered at Companies House
1 Dec 2023 to 30 Nov 2025
M:MBio is an innovative UK-SME supporting the British bioscience ecosystem in achieving scientific, clinical and commercial success through conducting deep data-led analysis and using machine-learning derived insights from its multi-omic oncology datasets. These datasets have the potential to support in predicting treatment-response based on individual pa...
